Don't Jump to an SGLT2 Inhibitor for Heart Failure
November 2019
You'll hear debate about whether to use an SGLT2 inhibitor (Farxiga, etc) to treat heart failure...in patients withOUT diabetes.
Prior evidence shows that patients WITH diabetes and CV disease or CV risks have fewer heart failure hospitalizations with Farxiga (dapagliflozin), Invokana (canagliflozin), or Jardiance (empagliflozin).
New evidence suggests Farxiga may benefit some heart failure patients...whether or not they have type 2 diabetes.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: APRN includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote